Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
It was disclosed that BWXT Medical Ltd., a division of BWX Technologies, Inc., and Fusion Pharmaceuticals Inc. had signed a preferred partner agreement for the delivery of actinium-225. According to the contract, BWXT Medical will supply Fusion with defined volumes…